EGFR and cancer: A total of 159 patients, with 88 patients from Hunan Cancer Hospital and 71 patients from Xiangya Hospital with EGFR-mutant locally advanced/advanced NSCLC who were treated with A+T were matched to 159 patients who were treated with single-agent T using propensity score matching with 1:1 ratio (Fig. 1).